Sign in
Not yet taking people in GermanyPhase 2/3

Tests a PET scan agent for imaging gastrointestinal cancers

Tests a PET scan tracer, 68Ga-FAPI-46, to image gastrointestinal cancers in adults.

Key facts

Who runs it
Universitaetsklinikum Essen AöR
Where
Essen and Muenster, GermanySee the 2 sites
Registry title
68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI)
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
150 people, planned
Started
3 Mar 2025
Planned end
30 Jun 2026
Type of study
Interventional
Record updated
16 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with proven or suspected cancer of the digestive system who are having a 68Ga-FAPI-46 PET scan, at first staging or re-staging.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Proven or suspected hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic, colorectal or oesophageal cancer, at initial staging or re-staging. At least one tumour lesion larger than 1cm (0.4 in).
Earlier treatment
No external beam radiation therapy within 1 month before enrolment to tumour lesions meant for surgery or biopsy. No chemotherapy, immunotherapy, biologic or targeted cancer therapy within 1 month before the PET scan.
Biomarker or test result
Participants must agree that a biopsy or tumour sample from surgery or biopsy within 8 weeks before or after enrolment is used to test FAP expression.

Main reasons for not taking part

  • Cannot give consent
  • Known or expected hypersensitivity to 68Ga-68-FAPI-46 or its excipients
  • Cannot lie flat or tolerate the PET scan
  • QTcF above 470 msec (women) or 450 msec (men), or congenital long QT syndrome
  • Pregnant or breast-feeding women

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Proven or suspected gastrointestinal cancers including: - Hepatocellular carcinoma - Cholangiocarcinoma - Gastric cancer - Pancreatic cancer - Colorectal cancer - Oesophageal cancer
  • At initial staging or re-staging of disease
  • At least one detectable tumour lesion with any diameter > 1cm
  • Intended or performed surgery of biopsy of tumor within 8 weeks before or 8 weeks after enrollment and participants consent to utilise biopsy/tumour specimen for immunohistochemical analysis of FAP expression
  • Age ≥ 18 years
  • Participant Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Women of child bearing potential (WOCBP), defines as all women physiologically capable of becoming pregnant, can only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test within 24 hours before radiopharmaceutical application

Who cannot take part

  • Prior external beam radiation therapy (EBRT) within 1 month of enrolment to tumour lesions intended for surgery or biopsy
  • Prior chemotherapy, immunotherapy, biologic or targeted oncologic therapy within 1 month prior 68Ga-FAPI-46 PET
  • Women of child bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, are not allowed to participate in this study, unless they are using highly effective methods of contraception during the interventional period. Highly effective contraception methods include: • True sexual abstinence: defined as refraining from heterosexual intercourse, when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception.• Vasectomised partner is a highly effective birth control method if the partner is the sole sexual partner of the study participant and the vasectomised partner has received medical assessment of the surgical success. • Bilateral tubal occlusion. • Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: - oral - intravaginal - transdermal• Progestogen-only hormonal contraception associated with inhibition of ovulation: - oral - injectable - implantable • Placement of an intrauterine device or intrauterine hormone-releasing system
  • Known or expected hypersensitivity to 68Ga-68-FAPI-46 or any of the relevant excipients
  • History of disease or condition that may critically interfere with participation in this study at the discretion of the investigators
  • QTcF >470 msec for females and QTcF >450 msec for males on screening ECG or history of congenital long QT syndrome
  • Post-menopausal women are allowed to participate in this study. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms), or six months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40mIU/mL or have had surgical bilateral oophorectomy or bilateral salpingectomy or hysterectomy or tubal ligation at least six weeks prior to screening. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
  • Participant cannot give consent for the study
  • Sexually active males must use a condom during intercourse during the interventional period. A condom is required to be used also by vasectomized men in order to prevent delivery of the study compound via seminal fluid
  • Participant can not lie flat or tolerate 68Ga-FAPI-46 PET imaging
  • Unwillingness or inability to comply with study and follow-up procedures
  • Pregnant, lactating, or breast-feeding women

Where in Germany

  • Universitaetsklinikum Essen (AoR)Essen, GermanyNot yet recruiting
  • Universitaet MuensterMuenster, GermanyNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the validity of 68Ga-FAPI-46 PET (positron emission tomography) inter- and intraindividual in patients with gastrointestinal cancers

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI)
Plain-language title
Tests a PET scan agent for imaging gastrointestinal cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 June 2026